GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » EV-to-EBITDA

Evaxion Biotech AS (Evaxion Biotech AS) EV-to-EBITDA : -1.17 (As of May. 03, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Evaxion Biotech AS's enterprise value is $25.68 Mil. Evaxion Biotech AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-22.02 Mil. Therefore, Evaxion Biotech AS's EV-to-EBITDA for today is -1.17.

The historical rank and industry rank for Evaxion Biotech AS's EV-to-EBITDA or its related term are showing as below:

EVAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1.3   Med: -0.78   Max: -0.64
Current: -1.17

During the past 7 years, the highest EV-to-EBITDA of Evaxion Biotech AS was -0.64. The lowest was -1.30. And the median was -0.78.

EVAX's EV-to-EBITDA is ranked worse than
100% of 466 companies
in the Biotechnology industry
Industry Median: 9.15 vs EVAX: -1.17

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-03), Evaxion Biotech AS's stock price is $3.98. Evaxion Biotech AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.100. Therefore, Evaxion Biotech AS's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Evaxion Biotech AS EV-to-EBITDA Historical Data

The historical data trend for Evaxion Biotech AS's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evaxion Biotech AS EV-to-EBITDA Chart

Evaxion Biotech AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - - -3.06 -1.77 -1.46

Evaxion Biotech AS Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.77 -0.84 -1.63 -0.84 -1.46

Competitive Comparison of Evaxion Biotech AS's EV-to-EBITDA

For the Biotechnology subindustry, Evaxion Biotech AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evaxion Biotech AS's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evaxion Biotech AS's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Evaxion Biotech AS's EV-to-EBITDA falls into.



Evaxion Biotech AS EV-to-EBITDA Calculation

Evaxion Biotech AS's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=25.678/-22.018
=-1.17

Evaxion Biotech AS's current Enterprise Value is $25.68 Mil.
Evaxion Biotech AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Evaxion Biotech AS  (NAS:EVAX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Evaxion Biotech AS's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.98/-8.100
=At Loss

Evaxion Biotech AS's share price for today is $3.98.
Evaxion Biotech AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.100.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Evaxion Biotech AS EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Evaxion Biotech AS (Evaxion Biotech AS) Business Description

Traded in Other Exchanges
N/A
Address
Dr. Neergaards Vej 5f, Hoersholm, DNK, DK-2970
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.